{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:55Z","timestamp":1786997935974,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"NICHD","doi-asserted-by":"publisher","award":["N01-HD-5-3226"],"award-info":[{"award-number":["N01-HD-5-3226"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["GS-23-F-0274M"],"award-info":[{"award-number":["GS-23-F-0274M"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.07.070","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T05:15:20Z","timestamp":1502169320000},"page":"4990-4996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice"],"prefix":"10.1016","volume":"35","author":[{"given":"Nahid","family":"Farzam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Ramon-Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonit","family":"Banet-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Lerner-Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Ashkenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kubler-Kielb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Vinogradov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schneerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.07.070_b0005","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1086\/386326","article-title":"Laboratory-confirmed shigellosis in the United States, 1989\u20132002: epidemiologic trends and patterns","volume":"38","author":"Gupta","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.070_b0010","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.07.070_b0015","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1371\/journal.pmed.0030353","article-title":"A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology","volume":"3","author":"von Seidlein","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.vaccine.2017.07.070_b0020","series-title":"Enterobacteriaceae, 2nd ed.","author":"Kaufmann","year":"1954"},{"key":"10.1016\/j.vaccine.2017.07.070_b0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2017.07.070_b0030","first-page":"S76","article-title":"Shigella species and serotypes among clinical isolates in Thailand from 2001 to 2005","volume":"92","author":"Pulsrikarn","year":"2009","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.vaccine.2017.07.070_b0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.070_b0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1432-1033.1978.tb20963.x","article-title":"Structural studies of Shigella flexneri O-antigens","volume":"91","author":"Kenne","year":"1978","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2017.07.070_b0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1432-1033.1979.tb13190.x","article-title":"Somatic antigens of Shigella. The structure of the specific polysaccharide of Shigella newcastle (Sh. flexneri type 6) lipopolysaccharide","volume":"98","author":"Dmitriev","year":"1979","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2017.07.070_b0050","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/JCM.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.07.070_b0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/MMBR.41.3.667-710.1977","article-title":"Serology, chemistry, and genetics of O and K antigens of Escherichia coli","volume":"41","author":"Orskov","year":"1977","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.vaccine.2017.07.070_b0060","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1574-6976.2008.00114.x","article-title":"Structure and genetics of Shigella O antigens","volume":"32","author":"Liu","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.07.070_b0065","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/IAI.61.9.3678-3687.1993","article-title":"Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids","volume":"19","author":"Taylor","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.07.070_b0070","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1128\/IAI.64.10.4074-4077.1996","article-title":"Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers","volume":"64","author":"Cohen","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.07.070_b0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.070_b0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1086\/314759","article-title":"Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children","volume":"179","author":"Ashkenazi","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.070_b0085","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/IAI.69.3.1351-1357.2001","article-title":"Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel","volume":"69","author":"Passwell","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.07.070_b0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.07.070_b0095","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134 year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.070_b0100","unstructured":"Annual report 2012, Central Laboratories, Ministry of Health, Israel. <http:\/\/www.health.gov.il\/PublicationsFiles\/LAB_JER_2012.pdf>."},{"key":"10.1016\/j.vaccine.2017.07.070_b0105","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1017\/S0950268814000260","article-title":"Recent trends in the epidemiology of shigellosis in Israel","volume":"142","author":"Bassal","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.07.070_b0110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/IAI.67.2.782-788.1999","article-title":"Strategy for Cross-protection among Shigella flexneri serotypes","volume":"67","author":"Noriega","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.07.070_b0115","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/IAI.59.12.4450-4458.1991","article-title":"Preparation, characterization, and immunogenicity of conjugates composed of the O- specific polysaccharide of Shigella dysenteriae type 1 (Shiga\u2019s bacillus) bound to tetanus toxoid","volume":"59","author":"Chu","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.07.070_b0120","series-title":"Program ELISA for Windows user\u2019s manual, version 2","author":"Plikaytis","year":"2005"},{"key":"10.1016\/j.vaccine.2017.07.070_b0125","first-page":"83","article-title":"Bacterial lipopolysaccharide extraction with phenol water and further applications of the procedure","volume":"5","author":"Westphal","year":"1965","journal-title":"Methods Carbohydr Chem"},{"key":"10.1016\/j.vaccine.2017.07.070_b0130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.carres.2006.09.017","article-title":"O-Acetylation of the O-specific polysaccharide isolated from Shigella flexneri serotype 2a","volume":"342","author":"Kubler-Kielb","year":"2007","journal-title":"Carbohyr Res"},{"key":"10.1016\/j.vaccine.2017.07.070_b0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1574-695X.2012.01000.x","article-title":"Shigella flexneri O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity","volume":"66","author":"Perepelov","year":"2012","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.07.070_b0140","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.07.070_b0145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/infdis\/166.2.316","article-title":"Human vaccination with Escherichia coli J5 mutant induces cross-reactive bactericidal antibody against Neisseria gonorrhoeae lipooligosaccharide","volume":"166","author":"Dale","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.070_b0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF01642875","article-title":"Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria","volume":"13","author":"Trautmann","year":"1985","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2017.07.070_b0155","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.vaccine.2003.11.025","article-title":"Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis","volume":"22","author":"Cross","year":"2004","journal-title":"Vaccine."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T08:00:51Z","timestamp":1602662451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17309787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":31,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17309787"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}